Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection
 
  • Details

Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection

Journal
Alimentary Pharmacology and Therapeutics
Journal Volume
49
Journal Issue
3
Pages
331-339
Date Issued
2019
Author(s)
TUNG-HUNG SU  
CHUN-JEN LIU  
TAI-CHUNG TSENG  
Chou S.-W
CHEN-HUA LIU  
HUNG-CHIH YANG  
SHANG-JU WU  
PEI-JER CHEN  
DING-SHINN CHEN  
CHI-LING CHEN  
JIA-HORNG KAO  
DOI
10.1111/apt.15101
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059159956&doi=10.1111%2fapt.15101&partnerID=40&md5=3edc03192c74f79f69bb031c7e905285
https://scholars.lib.ntu.edu.tw/handle/123456789/537624
Abstract
Background: Chronic hepatitis C infection is linked to lymphoma development. Aim: To investigate whether antiviral therapy prevents the risk of HCV-related lymphoma. Methods: Patients diagnosed with chronic hepatitis C were retrieved from the Taiwan National Health Insurance Research Database during 2004-2012. We included patients who received pegylated interferon and ribavirin (PegIFN/RBV) antiviral therapy for ?24?weeks (PegIFN/RBV cohort) or hepatoprotectants for ?90?days without antiviral therapy (HCV-untreated cohort). Both cohorts were matched by age, sex, and comorbidities through propensity scores and followed for newly diagnosed lymphoma or non-Hodgkin's lymphoma (NHL). Results: In total, 24?133 patients were included in both the PegIFN/RBV and HCV-untreated cohort. The lymphoma incidence was significantly higher in the untreated than in the treated cohort (66.48 vs 43.34 per 100?000 person-years, P?=?0.029). After adjusting for confounders, the patients who received PegIFN/RBV therapy were at a lower risk of developing lymphoma compared with the untreated patients (hazard ratio [HR]: 0.64, 95% confidence interval [CI]: 0.43-0.96, P?=?0.030). Moreover, this beneficial effect was mainly observed in patients with chronic hepatitis C <60?years old with a relative risk reduction of 51% for all lymphoma (HR: 0.49, 95% CI: 0.29-0.82, P?=?0.007) and 48% for non-Hodgkin's lymphoma (HR: 0.52, 95% CI: 0.30-0.91, P?=?0.022). The risk of all lymphoma or non-Hodgkin's lymphoma development after antiviral therapy was lowered to that of subjects without HCV. Conclusions: PegIFN/RBV-based antiviral therapy significantly reduced the risk of lymphoma, especially non-Hodgkin's lymphoma; the reduction was mostly among patients <60?years old. Early antiviral therapy for chronic hepatitis C is suggested. ? 2018 John Wiley & Sons Ltd
SDGs

[SDGs]SDG3

Other Subjects
peginterferon; ribavirin; alpha interferon; antivirus agent; macrogol; ribavirin; adult; age distribution; antiviral therapy; Article; cancer incidence; cancer risk; chronic hepatitis C; cohort analysis; combination drug therapy; comorbidity; confidence interval; controlled study; data base; female; follow up; hazard ratio; human; lymphoma; major clinical study; male; medical research; national health insurance; nonhodgkin lymphoma; population research; priority journal; propensity score; risk reduction; sex difference; Taiwan; time to treatment; treatment duration; chemistry; chronic hepatitis C; incidence; lymphoma; middle aged; Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lymphoma; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Taiwan
Publisher
Blackwell Publishing Ltd
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science